In the early 20th century, Alois Alzheimer identified neuroinflammation as a factor in the disease now named after him, noting the presence of microglia cells in his initial sketches.

TILT Biotherapeutics' one abstract highlights encouraging safety and efficacy findings of TILT-123 in patients with ovarian cancer.

May 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

selectION, Inc. declared the commencement of a Phase 1b study involving its leading candidate si-544 in adult individuals suffering from psoriasis vulgaris or psoriatic arthritis.

Novel Bispecific Antibody REGN7075 (EGFRxCD28) Shows Anti-Tumor Effects with Libtayo® (cemiplimab); Findings to be Presented at ASCO.

I-Mab Releases Promising Phase 1 Results for PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024.

BioAtla to Showcase Phase 1 Evalstotug Clinical Trial Outcomes Highlighting Clinical Benefits at the 2024 ASCO Annual Conference.

Sensei Biotherapeutics, Inc. has announced promising clinical results from the dose-escalation segment of its Phase 1/2 study on SNS-101.

Coherus BioSciences, Inc. presented results from the CHS-114 monotherapy dose escalation part of its Phase 1 trial at the ASCO Annual Meeting.

Cure Genetics Revealed Positive Safety and Effectiveness Data for CAR-NKT Treatment CGC729 in RCC at ASGCT 2024.

Abdera Therapeutics Inc. has revealed that the U.S. Food and Drug Administration has approved their Investigational New Drug application for ABD-147.

Aulos Bioscience revealed preliminary outcomes from its Phase 1/2 study of AU-007.